Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
79.87
+1.58 (+2.02%)
4:00:00 PM EDT: $79.84 -0.03 (-0.04%)
Products, Earnings Announcements

Merck Presents New Data For Three Investigational Medicines At ESMO Virtual Congress 2020

Published: 09/20/2020 14:31 GMT
Merck & Co Inc (MRK) - Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at Esmo Virtual Congress 2020.
Initiate Phase 3 Study of Vibostolimab in Non-small Cell Lung Cancer in First Half of 2021.
Vibostolimab As Monotherapy Or in Combination With Keytruda Had a Manageable Safety Profile.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.